Healthcare ❯ Pharmaceuticals

Vaccines

COVID-19 Vaccines COVID-19 Vaccine RSV Vaccine Covid-19 COVID-19 HPV Vaccine HPV Vaccines Covid-19 Vaccine AstraZeneca Covid Vaccine Safety CSL's Seqirus Immunization Products Safety Data Covid Vaccine mRNA Technology Combination Vaccines Regulatory Affairs Influenza Vaccine Production Injectable Treatments Gardasil Manufacturing Meningitis B Vaccine Specific Vaccines Vaccine Development Adult Immunizations COVID-19 Treatments Mpox Vaccine Covid-19 Vaccines Sales Decline Flu Vaccination Public Health Vaccine Efficacy

Pfizer Posts Higher Q1 Sales but Lower Profit, Raising Fresh Questions About Its Dividend

Income investors face a tough tradeoff over thin coverage of the payout.

Moderna Reaches Up to $2.25 Billion LNP Patent Settlement, Pays $950 Million Upfront

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Pfizer Sets 2026 Targets Below Wall Street as COVID Sales Fade, Patent Pressure Builds

Pfizer Lifts 2025 EPS Outlook, Targets $7.7 Billion in Savings as Dividend Draws Interest

Pfizer’s Updated COVID-19 Vaccine Shows Strong Phase 3 Immune Response for 2025–2026 Formula

Merck Launches $3 Billion Cost-Optimization Program Following Q2 Revenue Miss

House Judiciary Committee Subpoenas Pfizer Scientist Over 2020 Vaccine Timing Allegations